Table 1.
Currently active clinical trials targeting the microenvironment of PDA.
| Target | Agent | Combination | Identifier | Phase | Subjects |
|---|---|---|---|---|---|
| CCR2/5 | BMS-813160 | Chemotherapy or Nivolumab | NCT03184870 | 1/2 | Pancreatic cancer |
| GVAX, Nivolumab and SBRT | NCT03767582 | 1/2 | Locally Advanced PDA | ||
| CD40 | CDX-1140 | Pembrolizumab, or chemotherapy | NCT03329950 | 1 | Pancreatic adenocarcinoma |
| Selicrelumab | Atezolizumab + Chemotherapy | NCT03193190 | 1/2 | Metastatic pancreatic ductal adenocarcinoma | |
| CSF1R | IMC-CS4 | GVAX/CY and Pembrolizumab | NCT03153410 | 1 | Pancreatic cancer |
| CTLA-4 | Ipilimumab | Nab-Paclitaxel/Gemcitabine, Nivolumab and SBRT | NCT04247165 | 1/2 | Locally advanced pancreatic cancer |
| Ipilimumab + Nivolumab | Radiotherapy | NCT02866383 | 2 | Pancreatic cancer/Metastastic pancreatic cancer | |
| NCT03104439 | 2 | ||||
| NCT04361162 | 2 | ||||
| Tremelimumab + Durvalumab | Minimally invasive surgical microwave ablation | NCT04156087 | 2 | Non-resectable pancreatic cancer | |
| CTLA-4 + LAG3 | XmAb22841 | Monotherapy/Pembrolizumab | NCT03849469 | 1 | Pancreatic cancer |
| CXCR1/2 | SX-682 | Nivolumab | NCT04477343 | (phase) 1 | Pancreatic cancer |
| DC | DC Vaccine | NCT03592888 | Pancreatic adenocarcinoma | ||
| NCT04157127 | (phase) 1 | ||||
| NCT04627246 | |||||
| GM-CSF | GVAX/CY | NCT01088789 | 2 | Pancreatic cancer | |
| Nivolumab | NCT02451982 | 1/2 | Pancreatic cancer | ||
| IDO1 inhibitor (Epacadostat), Pembrolizumab, and CRS-207 | NCT03006302 | 2 | Metastatic pancreatic adenocarcinoma | ||
| Nivolumab and SBRT | NCT03161379 | 2 | Pancreatic cancer | ||
| CRS-207, Nivolumab, and Ipilimumab | NCT03190265 | 2 | Pancreatic cancer | ||
| OH2 (oncolytic virus expressing GM-CSF) | NCT04637698 | 1/2 | Locally advanced/metastatic pancreatic cancer | ||
| IL-1β | Canakinumab | Spartalizumab, Nab-paclitaxel, and Gemcitabine | NCT04581343 | 1 | Metastatic pancreatic ductal adenocarcinoma |
| IL-12 | Oncolytic adenovirus expression IL-12 | Standard chemotherapy | NCT03281382 | 1 | Metastastic pancreatic cancer |
| IL-6 | Siltuximab | Spartalizumab | NCT04191421 | 1/2 | Metastatic pancreatic adenocarcinoma |
| Tocilizumab | Nab-Paclitaxel and Gemcitabine | NCT02767557 | 2 | Unresectable panreatic carcinoma | |
| Ipilimumab, Nivolumab and SBRT | NCT04258150 | 2 | Pancreatic cancer | ||
| PD-1 | Cemiplimab | Plerixafor | NCT04177810 | 2 | Metastastic pancreatic cancer |
| Motixafortide (CXCR4 inhibitor), Nab-paclitaxel, and Gemcitabine | NCT04543071 | 2 | Pancreatic cancer | ||
| Nivolumab | Losartan, Folfirinox and SBRT | NCT03563248 | 2 | Pancreatic cancer | |
| Tadalafil and vancomycin | NCT03785210 | 2 | Metastatic liver cancer from pancreatic cancer | ||
| FT500 (iPSC-derived NK cell product) | NCT03841110 | 1 | Pancreatic cancer | ||
| Chemotherapy | NCT03970252 | 1/2 | Resectable pancreatic cancer | ||
| Stereotactic radiotherapy | NCT04098432 | 1/2 | Locally advanced non-resectable pancreatic cancer | ||
| Irreversible electroporation | NCT04212026 | 2 | Metastastic pancreatic cancer | ||
| SX-682 (CXCR1/2 inhibitor) | NCT04477343 | 1 | Pancreatic ductal adenocarcinoma | ||
| Pembrolizumab | Neoadjuvant chemoradiation | NCT02305186 | 1/2 | Resectable pancreatic cancer | |
| CPI-006 (CD73 antibody) | NCT03454451 | 1 | Pancreatic cancer | ||
| SBRT | NCT03716596 | 1 | Pancreatic cancer | ||
| Defactinib | NCT03727880 | 2 | Resectable pancreatic ductal adenocarcinoma | ||
| Lenvatinib (VEGFR inhibitor) | NCT03797326 | 2 | Pancreatic cancer | ||
| GB1275 (CD11b modulator) | NCT04060342 | 1/2 | Pancreatic adenocarcinoma | ||
| NT-I7 (Efineptakin Alfa) | NCT04332653 | 1/2 | Pancreatic cancer | ||
| EGFR/TGFβ Fusion Protein BCA101 | NCT04429542 | 1 | Pancreatic cancer | ||
| PD-L1 | Durvalumab | Stereotactic ablative body radiotherapy (SABR) | NCT03245541 | 1/2 | Pancreatic adenocarcinoma |
| Oleclumab (CD73 antibody) and chemotherapy | NCT03611556 | 1/2 | Metastatic pancreatic adenocarcinoma | ||
| TGFβR1 | PF-06952229 | NCT03685591 | 1 | Pancreatic neoplasms |
Clinical trial identifier from https://clinicaltrials.gov. CCR, C-C motif chemokine receptor; CSF1R, colony-stimulating factor 1 receptor; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CXCR, C-X-C motif chemokine receptor; DC, dendritic cell; GM-CSF, granulocyte-macrophage colony-stimulating factor; GVAX, GM-CSF gene transduced irradiated prostate cancer vaccine cells; IDO1, indoleamine 2,3-dioxygenase 1; LAG3, lymphocyte activating 3; PD-1, anti-programmed cell death 1; PDA, pancreatic ductal adenocarcinoma; PD-L1, programmed cell death ligand 1; SBRT, stereotactic body radiation; TGFβR, transforming growth factor β receptor.